Skip to main content

Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.

Publication ,  Journal Article
Li, G; Keenan, AC; Young, JC; Hall, MJ; Pamuklar, Z; Ohman, EM; Steinhubl, SR; Smyth, SS
Published in: Arterioscler Thromb Vasc Biol
August 2007

UNLABELLED: OBJECTIVES The objective of this study was to determine whether adjunctive therapy during percutaneous coronary intervention (PCI) affects markers of systemic inflammation or platelet activation. Despite different mechanisms of action, direct-thrombin inhibition with bivalirudin during PCI provided similar protection from periprocedural and chronic ischemic complications as compared with unfractionated heparin (UFH) plus planned use of GPIIb/IIIa antagonists in the REPLACE-2 and ACUITY trials. METHODS AND RESULTS: Patients undergoing nonurgent PCI of a native coronary artery were randomized to receive adjunctive therapy with bivalirudin or UFH+eptifibatide. Interleukin (IL)-6 and C-reactive protein (CRP) transiently increased in both groups after PCI. In the UFH+eptifibatide, but not the bivalirudin group, myeloperoxidase (MPO) levels were elevated 2.3-fold above baseline (P=0.004) immediately after PCI. In an in vitro assay, heparin and to a lesser extent enoxaparin, but not bivalirudin or eptifibatide, stimulated MPO release from and binding to neutrophils and neutrophil activation. A mouse model of endoluminal femoral artery denudation was used to investigate further the importance of MPO in the context of arterial injury. CONCLUSIONS: Adjuvant therapy during PCI may have undesired effects on neutrophil activation, MPO release, and systemic inflammation.

Duke Scholars

Published In

Arterioscler Thromb Vasc Biol

DOI

EISSN

1524-4636

Publication Date

August 2007

Volume

27

Issue

8

Start / End Page

1850 / 1856

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Reference Values
  • Recombinant Proteins
  • Probability
  • Peroxidase
  • Peptides
  • Peptide Fragments
  • Neutrophils
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, G., Keenan, A. C., Young, J. C., Hall, M. J., Pamuklar, Z., Ohman, E. M., … Smyth, S. S. (2007). Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol, 27(8), 1850–1856. https://doi.org/10.1161/ATVBAHA.107.144576
Li, Guohong, Alison C. Keenan, Justin C. Young, Margaret J. Hall, Zehra Pamuklar, E Magnus Ohman, Steven R. Steinhubl, and Susan S. Smyth. “Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.Arterioscler Thromb Vasc Biol 27, no. 8 (August 2007): 1850–56. https://doi.org/10.1161/ATVBAHA.107.144576.
Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1850–6.
Li, Guohong, et al. “Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.Arterioscler Thromb Vasc Biol, vol. 27, no. 8, Aug. 2007, pp. 1850–56. Pubmed, doi:10.1161/ATVBAHA.107.144576.
Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, Steinhubl SR, Smyth SS. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1850–1856.

Published In

Arterioscler Thromb Vasc Biol

DOI

EISSN

1524-4636

Publication Date

August 2007

Volume

27

Issue

8

Start / End Page

1850 / 1856

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Severity of Illness Index
  • Reference Values
  • Recombinant Proteins
  • Probability
  • Peroxidase
  • Peptides
  • Peptide Fragments
  • Neutrophils
  • Middle Aged